Johnson & Johnson (JNJ) Operating Margin (2009 - 2026)
Johnson & Johnson (JNJ) posted Operating Margin of 28.21% for Q2 2026, up 6.68% sequentially from 26.44% in Q1 2026, and up 22.0% YoY from 23.12% in Q2 2025.
Johnson & Johnson (JNJ) Operating Margin (2009 - 2026) Analysis & Trends
Johnson & Johnson has reported Operating Margin for 18 years, with the latest figure at 28.21% in Q2 2026.
- Quarterly Operating Margin rose 22.0% year-over-year to 28.21% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 26.59% (up 291.0% YoY) and the FY2025 annual result came in at 26.93%, up 327.0% from the prior year.
- Operating Margin grew to 28.21% in Q2 2026 per JNJ's latest filing, from 26.44% in the prior quarter.
- Over five years, Operating Margin peaked at 48.19% in Q1 2023 and troughed at 15.98% in Q4 2024.
- A 5-year average of 26.36% and a median of 26.95% in 2023 frame the typical range for Operating Margin.
- The widest YoY moves for Operating Margin: up 782 bps in 2023, down 2832 bps in 2023.
- Over 5 years, Operating Margin stood at 26.5% in 2022, then fell by 25 bps to 19.87% in 2023, then retreated by 20 bps to 15.98% in 2024, then jumped by 40 bps to 22.42% in 2025, then advanced by 26 bps to 28.21% in 2026.
- According to Business Quant data, Operating Margin over the past three periods registered 28.21%, 26.44%, and 22.42% for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 653.51 Bn | 632.75 Bn | 17.26 Bn | 28.21% |
| 2 | AbbVie | 470.18 Bn | 463.61 Bn | 12.70 Bn | 37.86% |
| 3 | Merck | 376.85 Bn | 369.71 Bn | 12.21 Bn | -3.52% |
| 4 | Novartis Ag | 303.27 Bn | 295.58 Bn | 11.24 Bn | 32.97% |
| 5 | Astrazeneca | 257.42 Bn | 252.52 Bn | 12.86 Bn | 20.57% |
| 6 | Amgen | 236.70 Bn | 222.71 Bn | 7.24 Bn | 34.95% |
| 7 | Gilead Sciences | 182.16 Bn | 178.98 Bn | 6.22 Bn | -133.21% |
| 8 | Pfizer | 159.30 Bn | 147.60 Bn | 10.94 Bn | 28.37% |
| 9 | Gsk | 106.12 Bn | 101.95 Bn | 8.24 Bn | 5.72% |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | 124.39% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 28, 2026 | 28.21% |
| Mar 29, 2026 | 26.44% |
| Dec 28, 2025 | 22.42% |
| Sep 28, 2025 | 29.31% |
| Jun 29, 2025 | 27.99% |
| Mar 30, 2025 | 28.24% |
| Dec 29, 2024 | 15.98% |
| Sep 29, 2024 | 22.42% |
| Jun 30, 2024 | 28.82% |
| Mar 31, 2024 | 27.63% |
| Dec 31, 2023 | 19.87% |
| Oct 1, 2023 | 26.88% |
| Jul 2, 2023 | 27.01% |
| Apr 2, 2023 | 27.36% |
| Jan 1, 2023 | 48.19% |
| Oct 2, 2022 | 26.50% |
| Jul 3, 2022 | 19.19% |
| Apr 3, 2022 | 21.94% |
| Oct 3, 2021 | 28.31% |
| Jul 4, 2021 | 26.60% |